Anti-Tau Antibody

Cell Markers, Neuronal Markers, Axonal Markers, Neurodegenerative Disease, Alzheimer's Disease

United States

55-62 kDa

Phosphate-buffered (10 mM) isotonic (0.9%, w/v) saline (“PBS, " pH 7.2) with sodium azide (0.02%, w/v) added as a preservative.

1:1000-1:2000 for immunohistochemistry and immunocytochemistry using 2% paraformaldehyde-fixed tissues or cells. Please note that these dilutions are meant to serve as starting points, and that optimal dilutions may vary.

Antipeptide antibodies were generated in chickens against two sequences shared between the mouse (P10637.3) and human (P10636.5) gene products. Neither of these sequences contain phosphorylated serine or threonine residues, so these Tau antibodies recognize both the euphosphorylated and hyperphosphorylated forms of Tau. Antibodies were affinity-purified from IgY fractions prepared from yolks collected from hyperimmunized hens. These antibodies have been validated with human, mouse and rat tissues.

Human Tau protein (i.e., microtubule-associated protein tau isoform 1) is a 78, 902 dalton protein (758 amino acids) expressed in cortical neurons of the CNS. In normal individuals, tau contains moderate degrees of phosphorylation on various serine and threonine residues scattered throughout the N-terminal half of this protein. However in various neurodegenerative diseases, such as Alzheimer's disease, Tau becomes hyperphosphorylated on these residues, leading to the pathological formation of intracellular "neurofibrillary tangles." Such tangles are hallmarks of Alzheimer's disease, as well as various other neurodegenerative diseases, collectively known as the "tauopathies."

Polyclonal

1:5000-1:10000

Human, Mouse, Rat

12 months from receipt of product

Chickens were immunized with two synthetic peptide / keyhole limpet hemocyanin (KLH) conjugates. These synthetic peptides corresponded to different and nonphosphorylated regions of the Tau gene product, but are shared between the human (NP_05819, NCBI) and mouse (P01637, NCBI) sequences. After repeated injections, immune eggs were collected, and the IgY fractions were purified from the yolks. These IgY fractions were then affinity purified using a peptide column, and the concentrations of the eluates adjusted to 200 µg/mL. Finally, equal volumes of both of these affinity-purified anti-peptide antibodies were mixed, and the preparation was filter-sterilized.